Joshua A. Homer

Joshua A. Homer

Auto-generated profile, based on publicly available information

Joshua A. Homer

Cancer Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
CSChristopher J. Smedley
Christopher J. Smedley
JHJoshua A. Homer
Joshua A. Homer
TGTimothy L. Gialelis
Timothy L. Gialelis
ABAndrew S. Barrow
Andrew S. Barrow
RKRebecca A. Koelln
Rebecca A. Koelln
JMJohn Edward Moses
John Edward Moses

3 August 2023 in Nature Reviews Methods Primers
Verified
Journal Article
Closed access
PDF file
JHJoshua A. Homer
Joshua A. Homer
LXLong Xu
Long Xu
NKNamitharan Kayambu
Namitharan Kayambu
QZQinheng Zheng
Qinheng Zheng
ECEun Joung Choi
Eun Joung Choi
JMJohn Edward Moses
John Edward Moses

15 October 2024 in Nature Reviews Bioengineering
Verified
Journal Article
Closed access
PDF file
JHJoshua A. Homer
Joshua A. Homer
RJRobert M. Johnson
Robert M. Johnson
RKRebecca A. Koelln
Rebecca A. Koelln
AMAdam D. Moorhouse
Adam D. Moorhouse
JMJohn Edward Moses
John Edward Moses

4 March 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
JHJoshua A. Homer
Joshua A. Homer
RKRebecca A. Koelln
Rebecca A. Koelln
ABAndrew S. Barrow
Andrew S. Barrow
TGTimothy L. Gialelis
Timothy L. Gialelis
ZBZlata Boiarska
Zlata Boiarska
JMJohn Edward Moses
John Edward Moses
The Accelerated SuFEx Click Chemistry (ASCC) protocol, adapted to a 96-well plate format, has been applied to the late-stage derivatization of bioactive molecules and array synthesis of anticancer agents, showcasing its potential for drug discovery.

3 April 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AOAlessandra Ottonello
Alessandra Ottonello
JWJessica A. Wyllie
Jessica A. Wyllie
OYOussama Yahiaoui
Oussama Yahiaoui
SSShoujun Sun
Shoujun Sun
RKRebecca A. Koelln
Rebecca A. Koelln
JMJohn Edward Moses
John Edward Moses
The alarming rise in superbugs that are resistant to drugs of last resort, including vancomycin-resistant enterococci and staphylococci, has become a significant global health hazard. Here, we report the click chemistry synthesis of an unprecedented class of shapeshifting vancomycin dimers (SVDs) that display potent activity against bacteria that are resistant to the parent drug, including the ESKAPE pathogens, vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), as well as vancomycin-resistant S. aureus (VRSA). The shapeshifting modality of the dimers is powered by a triazole-linked bullvalene core, exploiting the dynamic covalent rearrangements of the fluxional carbon cage and creating ligands with the capacity to inhibit bacterial cell wall biosynthesis. The new shapeshifting antibiotics are not disadvantaged by the common mechanism of vancomycin resistance resulting from the alteration of the C-terminal dipeptide with the corresponding d -Ala- d -Lac depsipeptide. Further, evidence suggests that the shapeshifting ligands destabilize the complex formed between the flippase MurJ and lipid II, implying the potential for a new mode of action for polyvalent glycopeptides. The SVDs show little propensity for acquired resistance by enterococci, suggesting that this new class of shapeshifting antibiotic will display durable antimicrobial activity not prone to rapidly acquired clinical resistance.

9 November 2021 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
CSChristopher J. Smedley
Christopher J. Smedley
JHJoshua A. Homer
Joshua A. Homer
TGTimothy L. Gialelis
Timothy L. Gialelis
ABAndrew S. Barrow
Andrew S. Barrow
RKRebecca A. Koelln
Rebecca A. Koelln
JMJohn Edward Moses
John Edward Moses